IRC-assessed ORR in prespecified subgroups (efficacy analysis set). Figure is adapted and updated from Opat S et al.^11 (Fig2) BR, bendamustine + rituximab; CHOP, cyclophosphamide + doxorubicin + vincristine + prednisone; ECOG, Eastern Cooperative Oncology Group; LDi, longest diameter; LDH, lactate dehydrogenase; NMZL, nodal marginal zone lymphoma; R, rituximab; SMZL, splenic marginal zone lymphoma.